Phase II/III study of MultiStem for the prevention and treatment of graft-versus-host disease in patients undergoing haematopoietic stem cell transplantation

Trial Profile

Phase II/III study of MultiStem for the prevention and treatment of graft-versus-host disease in patients undergoing haematopoietic stem cell transplantation

Planning
Phase of Trial: Phase II/III

Latest Information Update: 10 Mar 2016

At a glance

  • Drugs Allogeneic stem cell therapy Athersys (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Mar 2016 According to an Athersys company media release, this trial has received Special Protocol Assessment designation from the Food and Drug Administration and positive opinion from European Medicines Agency through its Scientific Advice procedure regarding the registration of this study.
    • 13 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top